URGENT: This Altcoin Opportunity Won’t Wait – Act Now

All of our key indicators are flashing the same signal: an altcoin season is fast approaching. And if you know anything about crypto, you know that altcoin seasons are where some of the biggest gains happen.

Rita A. Karachun net worth and biography

Rita Karachun Biography and Net Worth

VP of Merck & Co., Inc.

Rita Karachun is the Senior Vice President Finance - Global Controller for Merck & Co., Inc. As Global Controller, Ms. Karachun is responsible for all accounting and reporting aspects for Merck. In this role, She has oversight responsibility for all accounting at Merck including developing accounting policies for Merck, the interpretation of those policies for specific transactions and the consolidation of Merck’s results. Ms. Karachun also oversees Merck’s external reporting, the accounting for business development activity as well as managing the financial supply chain of intercompany sales transactions. Ms. Karachun joined Merck in 2007 as an Assistant Controller for Schering-Plough and continued as Assistant Controller for Merck after the merger between Schering-Plough and Merck in 2009. In these roles, She led the integration of Schering-Plough’s acquisition of OBS, a Netherlands-based company and also led the implementation of a global consolidation system. Before joining Schering-Plough, She worked at AT&T Corp. and it’s leasing subsidiary, AT&T Capital, for 16 years. Her last position with AT&T was Assistant Controller and Chief Accountant. She held a variety of roles at AT&T of increasing responsibility, including investor relations manager and controller of corporate units. Prior to AT&T, she was a senior at Arthur Andersen & Co., Ms. Karachun is a certified public accountant and earned a B.S. degree in accounting from Fairleigh Dickinson University, graduating Summa Cum Laude.

What is Rita A. Karachun's net worth?: The estimated net worth of Rita A. Karachun is at least $4.48 million as of May 4th, 2023. Dr. Karachun owns 45,710 shares of Merck & Co., Inc. stock worth more than $4,481,866 as of December 21st. This net worth estimate does not reflect any other investments that Dr. Karachun may own. Learn More about Rita A. Karachun's net worth.
How do I contact Rita A. Karachun?: The corporate mailing address for Dr. Karachun and other Merck & Co., Inc. executives is 2000 GALLOPING HILL ROAD, KENILWORTH NJ, 07033. Merck & Co., Inc. can also be reached via phone at (908) 740-4000 and via email at [email protected]. Learn More on Rita A. Karachun's contact information.
Has Rita A. Karachun been buying or selling shares of Merck & Co., Inc.?: Rita A. Karachun has not been actively trading shares of Merck & Co., Inc. during the past quarter. Most recently, Rita A. Karachun sold 15,875 shares of the business's stock in a transaction on Thursday, May 4th. The shares were sold at an average price of $117.53, for a transaction totalling $1,865,788.75. Following the completion of the sale, the vice president now directly owns 45,710 shares of the company's stock, valued at $5,372,296.30. Learn More on Rita A. Karachun's trading history.
Who are Merck & Co., Inc.'s active insiders?: Merck & Co., Inc.'s insider roster includes Sanat Chattopadhyay (Insider), Frank Clyburn (EVP), Robert Davis (CFO), Richard Deluca (EVP), Kenneth Frazier (Insider), Julie Gerberding (EVP), Clark Golestani (EVP), Michael Holston (EVP), Rita Karachun (VP), Caroline Litchfield (CFO), Steven Mizell (EVP), Johannes Oosthuizen (Insider), Joseph Romanelli (Insider), Ashley Watson (SVP), and Wendell Weeks (Director). Learn More on Merck & Co., Inc.'s active insiders.
Are insiders buying or selling shares of Merck & Co., Inc.?: During the last year, insiders at the sold shares 2 times. They sold a total of 51,694 shares worth more than $6,545,285.10. The most recent insider tranaction occured on February, 13th when insider Joseph Romanelli sold 1,000 shares worth more than $124,890.00. Insiders at Merck & Co., Inc. own 0.1% of the company. Learn More about insider trades at Merck & Co., Inc..
Information on this page was last updated on 2/13/2024.

Rita A. Karachun Insider Trading History at Merck & Co., Inc.

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
5/4/2023	Sell	15,875	$117.53	$1,865,788.75	45,710
10/28/2022	Sell	31,997	$100.34	$3,210,578.98	41,103
11/3/2021	Sell	25,000	$88.45	$2,211,250.00
2/14/2019	Sell	64,662	$78.96	$5,105,711.52	53,327
8/2/2018	Sell	5,000	$65.01	$325,050.00

Rita A. Karachun Buying and Selling Activity at Merck & Co., Inc.

Merck & Co., Inc. Company Overview

Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes under the Keytruda, Bridion, Adempas, Lagevrio, Belsomra, Simponi, and Januvia brands, as well as vaccine products consisting of preventive pediatric, adolescent, and adult vaccines under the Gardasil/Gardasil 9, ProQuad, M-M-R II, Varivax, RotaTeq, Live Oral, Vaxneuvance, Pneumovax 23, and Vaqta names. The Animal Health segment discovers, develops, manufactures, and markets veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as digitally connected identification, traceability, and monitoring products. The company serves drug wholesalers and retailers, hospitals, and government agencies; managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions; and physicians, wholesalers, government entities, veterinarians, distributors, animal producers, farmers, and pet owners. It has development and commercialization agreement for three of Daiichi Sankyo's deruxtecan ADC candidates, which include patritumab deruxtecan, ifinatamab deruxtecan, and raludotatug deruxtecan for the treatment of multiple solid tumors both as monotherapy and/or in combination with other treatments; and AstraZeneca PLC to co-development and co-commercialize AstraZeneca's Lynparza products for multiple cancer types, and Koselugo for multiple indications. The company also has a collaboration agreement with Eisai Co., Ltd., Bayer AG, and Ridgeback Biotherapeutics LP, as well Moderna, Inc. Merck & Co., Inc. was founded in 1891 and is headquartered in Rahway, New Jersey.

Today's Range

Now: $98.05

$97.90

$99.68

50 Day Range

MA: $102.25

$96.30

$111.54

2 Week Range

Now: $98.05

$94.48

$134.63

Volume

29,272,893 shs

Average Volume

9,418,368 shs

Market Capitalization

$248.03 billion

P/E Ratio

20.56

Dividend Yield

3.02%

Beta

0.39

URGENT: This Altcoin Opportunity Won’t Wait – Act Now

From Crypto Swap Profits | Ad

Crypto has officially entered the "banana zone" – that wild phase where prices can 1000x in days. It happens like clockwork every 4 years, during the December to February window of a Bitcoin halving year. This is where fortunes are made – often LITERALLY overnight.

>> Register for the Workshop Now